Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus

Exclusion Criteria

• •Diagnosis of hemorrhage brain disease on baseline head CT;
• •Iatrogenic and cardiogenic stroke;
• •Patients receiving thrombolysis or endovascular treatment;
• •Use of a GLP-1 analogue or any dipeptidyl peptidase-IV (DPP-IV) inhibitor within the 3 months prior to screening;
• •Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC);
• •Patients with pancreatitis or previous history of pancreatitis, inflammatory bowel disease and gastroparesis;
• •Pregnant, lactating women,or patients who are likely to have a pregnancy and plan to have one;
• •Allergic to liraglutide or excipients;
• •Congestive heart failure (NYHA class III-IV);
• •Severe liver and kidney dysfunction (AST/ALT is 3 times higher than the normal upper limit, serum creatinine is 3 times higher than the normal upper limit);
• •Patients with malignant tumors who are expected to have a survival period of less than three months;
• •Participated in other clinical trials of drugs within 3 months;
• •Researchers believe that patients who are not suitable for this clinical study.